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We identified 29 yeast isolates from 22 patients using the API ID32C panel. Twenty-eight of these isolates
were Candida norvegensis and one was C. inconspicua. Although C. norvegensis is considered a pseudohypha-
producing species, only one isolate produced pseudohyphae. Restriction enzyme analysis of PCR-amplified
ribosomal DNA with four different enzymes proved that all isolates were C. inconspicua.
The frequency of human infections caused by yeasts is in-
creasing. Candida albicans is still the opportunistic pathogenic
yeast most frequently isolated from humans with fungal dis-
eases; however, several non-C. albicans Candida species are
also cultured more and more frequently from different body
sites (3, 15). Preliminary identification of non-C. albicans Can-
dida species has been incorporated into the majority of routine
laboratory algorithms (18). In doubtful cases, additional tech-
niques are required to obtain a precise identification of the
isolated species, e.g., the determination of different biochem-
ical patterns with the API 20C and API ID32C systems (API/
ATB package inserts, BioMerieux, 1996). Recently, molecular
biology techniques have been introduced for the more precise
identification of Candida isolates (21, 22). This urgent need is
based on at least two factors: the spread of Candida species
resistant to antifungal agents (6) and the threat of nosocomial
Candida outbreaks (4). An additional advantage of these tech-
niques is the ability to differentiate between closely related
species or previously misidentified yeasts.
C. inconspicua and C. norvegensis are rarely isolated oppor-
tunistic pathogens (17, 20). During the past 5 years, the num-
ber of yeast isolates identified in the Laboratory for Bacterio-
logical Diagnostics, University of Debrecen, as C. inconspicua
or C. norvegensis increased from 3 to 4 per year to 29 per year
(in 2001), while the overall increase in the rate of yeast isola-
tion was only threefold (9). We could not reliably distinguish
the two species by traditional identification methods (with the
API ID32C system and detection of pseudohypha production)
because the species identities obtained by different methods
were contradictory. To precisely identify our isolates we ap-
plied ribosomal DNA (rDNA) analysis.
The genetic background of the method chosen can be sum-
marized as follows. The tandemly repeated rDNA genes of
yeasts contain highly conservative and less conservative re-
gions. Sequences coding for the 18S, 5.8S, and 25S rRNAs
evolved slowly during the phylogenesis of fungi; thus, they are
suitable for use as tools for discrimination and identification at
the interspecies or higher level. On the contrary, the internal
transcribed spacer region 1 (ITS1) and ITS2 rDNA regions are
more variable; thus, they can serve as a tool in the discrimina-
tion of closely related yeast species (21). Restriction enzyme
analysis of PCR-amplified rDNA is a superior typing method
suitable for correct identification, even with a large number of
yeast isolates. In addition, this method can correct misidenti-
fication results, which frequently occur during routine identi-
fication based on morphological and biochemical tests (22).
Of 22 patients sampled, 5 were outpatients, while 17 were
hospitalized (Medical School, University of Debrecen). The
outpatients had serious vaginitis and mycotic tonsillitis. Four-
teen of the 17 hospitalized patients had some condition that
predisposed them to infection (i.e., organ transplantation, ma-
lignancy, cystic fibrosis, or diabetes mellitus). The inpatients
were treated (and sampled) at different times (there was gen-
erally a time difference of at least a month between two pa-
tients) and at various clinics of the university, which are situ-
ated in separate buildings.
The samples yielding the yeast isolates studied were ob-
tained for routine microbiological examination. The majority
of the specimens were of the airway, with a few urine, wound,
and genital swab samples also obtained. The specimens were
plated directly onto Sabouraud dextrose agar (SDA) contain-
ing 500 g of chloramphenicol per ml and were incubated for
24 h at 37°C, followed by an additional incubation for 13 days
at room temperature. The colonies on SDA were transferred
to CHROMagar Candida (Becton Dickinson). Preliminary
identification was based on colony color. The germ tube test
(19) was also performed. We also examined the colonies for
pseudohypha formation on rice-agar-Tween (RAT) medium
(Dalmau technique) (13). For species identification, carbohy-
drate assimilation profiles were determined by the using API
ID32C panel (BioMerieux). We used C. inconspicua ATCC
16783, C. norvegensis ATCC 22977, and C. krusei ATCC 6258
type strains as reference strains. Yeast cultures were main-
tained on SDA at 4°C and in SDA-glycerol medium at 70°C.
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Fluconazole MICs were determined by use of the M27-A
NCCLS standard (11).
Total yeast DNA was isolated by the method of Hoffman
and Winston (5). Primers NS3 and ITS4 were used for the
amplification by PCR of an rDNA sequence approximately
1,900 bp long. The sequence comprises a part of small rDNA,
the 5.8S rDNA, and the two ITS regions (21). The PCR was
carried out in a 30-l reaction mixture containing 3 l of 10
PCR buffer, 1.5 l of 50 mM MgCl2, 0.1 l of 25 mM (each)
deoxynucleoside triphosphates, 1.6 U of DyNAzyme II DNA
polymerase (Finnzymes), 1 l of primers (ca. 2 pmol), and 4 l
of template (yeast) DNA. Amplification was performed by
using the PCR Sprint Thermal Cycler (Hybaid Ltd., Tedding-
ton, England) and standard conditions with 61.5°C as the an-
nealing temperature. The amplified products were digested
with the restriction enzymes MspI, RsaI, ScrFI, and HaeIII
(New England BioLabs) in separate reactions. The DNA frag-
ments generated by the restriction enzymes were separated by
conventional agarose gel electrophoresis. The gel was digi-
tized, photographed with Gel Documentation Equipment
(Bio-Rad), and analyzed with the Molecular Analyst Program
(Bio-Rad).
We isolated 29 yeasts from the 22 patients sampled. All
formed round white colonies on CHROMagar Candida, simi-
lar to C. norvegensis ATCC 22977 and C. inconspicua ATCC
16783, while C. krusei ATCC 6258 grew as rough spreading
pink colonies. The fluconazole MICs for the clinical isolates
varied between 16 and 64 g/ml; 25 isolates were dose-depen-
dent susceptible to fluconazole, and 4 were resistant to flucon-
azole. Identification to the species level was performed by the
API ID32C test (BioMerieux) and determination of pseudohy-
pha production on RAT medium, as summarized in Table 1.
Twenty-seven of the 29 isolates were identified as C. incon-
spicua/C. norvegensis, similar to the C. inconspicua and C. nor-
vegensis reference strains. The biocodes for the remaining two
isolates corresponded to an “acceptable identification” for the
Candida genus only and suggested that the isolates were either
C. krusei, C. inconspicua, or C. norvegensis. According to the
API ID32C identification system, esculin hydrolysis should be
tested to further differentiate among these three species. C.
norvegensis hydrolyzes esculin, while C. inconspicua and C.
krusei do not. Of our 29 clinical isolates, 28 hydrolyzed esculin,
as did the C. norvegensis ATCC 22977 reference strain, while 1
clinical isolate, C. inconspicua ATCC 16783, and C. krusei
ATCC 6258 did not (Table 1). On the basis of the results
obtained with the API ID32C system, 28 clinical isolates were
identified as C. norvegensis and one was identified as C. incon-
spicua. All three reference strains were correctly identified by
the API ID32C system.
All Candida isolates failed to produce chlamydospores and
germ tubes. Pseudohypha formation on Dalmau plates was
negative for all isolates except the C. krusei reference strain
and one clinical isolate, which became positive on the 2nd and
9th days after inoculation, respectively. As C. krusei and C.
norvegensis have been described to produce pseudohyphae on
Dalmau plates (7, 8) and C. inconspicua has not (10), the
pseudohypha production findings contradict the results of the
biochemical tests mentioned above.
Restriction enzyme analysis of the PCR-amplified rDNA
regions produced three typical patterns with any of the four
enzymes applied. One pattern was typical for the C. incon-
spicua ATCC 16783 strain and all 29 clinical isolates, the sec-
ond pattern was typical for the C. norvegensis ATCC 22977
reference strain, and the third pattern was typical for the C.
krusei ATCC 6258 reference strain. Typical patterns are illus-
trated in Fig. 1. This result clearly indicates that the 28 isolates
identified as C. norvegensis by the API ID32C system belong to
C. inconspicua.
The dramatic increase in human fungal infections is well
documented (4, 9). However, judgment of the etiological role
of an isolated fungus is very difficult and requires consideration
of the individual isolate (9). This report represents a further
example of the importance of correct identification of clinical
yeast isolates.
Use of only the esculin hydrolysis probe from the 31 bio-
chemical tests of the API ID32C panel is recommended to
discriminate between C. inconspicua and C. norvegensis. Ac-
cording to our results, this characteristic is variable among the
members of the species C. inconspicua; only one of the clinical
isolates and the type strain gave the expected result. C. krusei
can cause an additional complication in routine laboratory
work, because this yeast frequently shows assimilation profiles
similar to those of C. inconspicua and C. norvegensis (2, 12).
Fortunately, the commercial medium CHROMagar Candida
greatly facilitates the identification of C. krusei.
Interestingly, one clinical isolate of C. inconspicua produced
pseudohyphae on RAT medium. Thus, pseudohypha produc-
tion also seems to be an unreliable diagnostic tool for discrim-
ination of esculin-negative C. inconspicua and C. krusei strains,
which has been described earlier (13). Nho et al. (12) have also
demonstrated the unreliability of pseudohypha production.
As the two phenotype-based identification methods applied
gave contradictory results, we used rDNA analysis for defini-
tive species identification. A similar approach to the identifi-
cation of these biochemically similar three yeast species has
been described by Nho et al. (12), who examined C. incon-
spicua, C. norvegensis, and C. krusei strains obtained from the
BioMerieux stock collection. They demonstrated that HhaI
cuts the PCR products generated by the ITS1- and ITS4-
specific primers into six small restriction fragments for both C.
inconspicua (esculin negative) and C. norvegensis (esculin pos-
itive), and differences in restriction fragment lengths deter-
mined by sequencing were used for discrimination of the two
species. They obtained four fragments for C. krusei. Our
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Outpatients 0200010005 4 0 0 4
0200010001 1 0 0 1
Inpatients 0200010005 22 1 1a 22
0200010001 1 0 0 1
Total 28 1 1 28
a This isolate also hydrolysed esculin.
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method, which uses different primers and restriction enzymes,
proved to be capable of distinguishing the three species with-
out sequencing of the restriction fragments.
Several investigators have postulated that the observed shift
in the distribution of yeast isolates in clinical samples may be
due to the widespread use of fluconazole, which leads to the
emergence of yeasts less susceptible to fluconazole (14). In
addition to C. krusei, C. inconspicua and C. norvegensis are also
considered to possess decreased susceptibility to fluconazole
(1, 16, 20), which is confirmed by our results for C. inconspicua.
While a significant amount of data on C. krusei has been
gathered in the past few years, the information available on C.
inconspicua and C. norvegensis is scant. To address the ques-
tion of the occurrences and the roles of C. inconspicua and C.
norvegensis in human disease as well as the importance of their
fluconazole resistance, exact identification and reliable differ-
entiation of the two species are required. These facts also
underline the growing need for the application of molecular
biology methods during identification.
We thank our colleagues Cecília Miszti and Erzse´bet Falusi for
valuable help in performing the experiments.
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